Overview

Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease

Status:
Completed

Trial end date:
2014-01-01

Target enrollment:

Participant gender:

Summary

This study will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer in identifying abnormal (18F) flutemetamol uptake patterns which predict the conversion from aMCI to a b-amyloid associated clinically probable Alzheimer's disease.

Phase:

Phase 3

Details

Lead Sponsor:

GE Healthcare

Collaborators:

i3 Research
i3 Statprobe
Medpace, Inc.
Quintiles, Inc.

Treatments:

Flutemetamol